Citations

Clear

6273 citation(s) found for "To, Andrew".

MHC Class I deletion on pericytes alters lymphocyte infiltration during Theiler’s murine encephalomyelitis virus 2198
Maynes, Mark Andrew, Tian, Zichen, Thelwell, Javonte , Johnson, Aaron J. , Maynes, Mark A , Seady, Marina , Jin, Fang , Hansen, Michael J, Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.146 Get It

Abstract Description CD8 T cell induced blood-brain barrier (BBB) disruption is an established mechanism of neuropathology. The pericyte is a MHC class I expressing neurovascular unit cell type which is critical for maintaining BBB integrity. However, the importance of pericyte antigen-restricted engagement by CD8 T cells is not fully understood. To determine the function of pericyte MHC Class I antigen presentation, we crossed the Pdgfrβ-creERT2 mouse to our novel H-2Db LoxP mouse developed by our laboratory. This transgenic mouse approach enabled us to target pericytes during neuroinflammation. We observed robust knockdown of H-2Db on Pdgfrβ+ pericytes during TMEV infection in these animals. The effect of conditional H-2Db knockdown on this cell type resulted in increased CD4 T cell, CD8 T cell, and B cells infiltration of the brain during TMEV infection, demonstrating an important role of Pdgfrβ+ pericytes for immune cell recruitment into the CNS. To our knowledge, this is the first study demonstrating an important role for MHC class I antigen presentation by pericytes in a murine model of neuroinflammation. Funding Sources Supported by R01NS122174 and R01NS103212 Topic Categories Neuroimmunology (NEUR)
Recruitment of diverse immune cells to dura mater during Theiler’s virus infection is altered in MHC class I deficiency 3541
Tian, Zichen, Maynes, Mark Andrew, Thelwell, Javonte , Jin, Fang, Hansen, Michael, Johnson, Aaron J. , Maynes, Mark A , Hassani, Asma , Seady, Marina , Jin, Fang, Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1332 Get It

Abstract Description The dura mater of the meninges recruits immune cells for CNS surveillance and response to infections, serving as a critical interface between the brain and the peripheral immune system. Theiler’s murine encephalomyelitis virus (TMEV) infection is a model neurotropic virus for which MHC class I molecules are critical for sterilizing immunity. Using spectral flow cytometry, we profiled the immune response in the dura mater in healthy and TMEV-infected wildtype mice. Acute TMEV infection resulted in the infiltration of diverse immune cell types into the dura mater, including increased cDC1, pDCs, monocytes, NK cells, CD4 T cells, and CD8 T cells. We next examined the importance of MHC class I molecules on diverse immune cell populations in the dura mater during acute TMEV infection. MHC class I deficiency resulted in increased numbers of CD4 T cells with high expression of PD1 in MHC class I-/- (H-2Kb-/-, H-2Db-/-) mice compared to WT mice 7 days post TMEV infection. This demonstrated the importance of MHC class I and CD8 T cells in modulating dura immune cell populations and implies a compensatory shift toward a CD4 T cell response during acute infection. Subsequent studies employing in vivo cell-specific ablation of MHC class I molecules in discrete cell types will further define the impact of antigen presentation on immune regulation and inflammatory outcomes within the dura mater. Topic Categories Neuroimmunology (NEUR)
The Use of a Consumer-Grade Bioelectrical Impedance Analysis Device for Weight Certification in Collegiate Wrestling: Implications for Minimal Wrestling Weight Determination
Twohey, Eric , Dobbs, Ward C. , Malone, Conley M., Jones, Margaret T. , Malone, Conley M., Jagim, Andrew R.

Mayo Clinic

Journal of Strength & Conditioning Research | November 20, 2025 | Volume: 39 | Issue: 12 | Pages: 1321-1326

10.1519/jsc.0000000000005300 | PMID 42709702 Get It

Abstract Twohey, E, Dobbs, WC, Malone, CM, Fields, JB, Jones, MT, and Jagim, AR. The use of a consumer-grade bioelectrical impedance analysis device for weight certification in collegiate wrestling: Implications for minimal wrestling weight determination. J Strength Cond Res 39(12): 1321–1326, 2025—Wrestlers are required to complete a preseason weight certification assessment, which includes a weigh-in, a hydration test, and a body fat percentage (BF%) measurement. This information is then used to establish their minimal wrestling weight (MWW) and minimal weight class. Skinfold (SKF) is the primary method used for determining body fat for collegiate wrestling, yet impedance devices are being considered for use in the future. The purpose of this study was to examine differences in body fat and the resulting MWW values derived from SKF and a consumer-grade multifrequency bioelectrical impedance analysis (MFBIA) device. Thirty-one collegiate male wrestlers produced a urine sample for urine specific gravity assessment to ensure adequate hydration status. Subjects then completed a weigh-in, followed by 2 body composition assessments using a (a) MFBIA device and (b) skinfold calipers to determine body density and BF%. No significant differences were observed for estimates of BF% (SKF: 13.4 ± 2.8% vs. MFBIA: 14.0 ± 3.3%; p = 0.198) or computed MWW values (SKF: 69.8 ± 8.7 kg vs. MFBIA: 69.4 ± 9.7 kg; p = 0.348) between devices. When determining the minimal weight class for each device, there were discrepancies in 11 of the 31 wrestlers (35%). Although the current MFBIA device can provide an acceptable estimate of BF% and similar resulting MWW value at the group level, the methods cannot be used interchangeably.
Global prevalence of multidrug-resistant Candida auris in humans between 2015 and 2024: A systematic review and meta-analysis
Barwatt, Will J, Kottom, Theodore J. , Oladele, Rita , Limper, Andrew H. , Achilonu, Conrad C, Kottom, Theodore J , Oladele, Rita O , Limper, Andrew H , Achilonu, Conrad Chibunna , Ramatla, Tsepo A.

Mayo Clinic

Medical Mycology | November 20, 2025 | Volume: 63 | Issue: 12 | Pages: No page available

10.1093/mmy/myaf107 | PMID 41263492 Get It

Abstract Candida auris is an emerging fungal pathogen with high rates of multidrug resistance, posing a significant global health threat. Immunosuppressed patients are particularly vulnerable to multidrug-resistant (MDR) C. auris infections. This systematic review and meta-analysis (SR-MA) aimed to assess the global prevalence of MDR-C. auris isolates in humans and their resistance to antifungal drugs, primarily fluconazole (FLZ), voriconazole (VOR), and amphotericin B (AmB). A comprehensive search was conducted in PubMed, Scopus, and ScienceDirect databases on published studies regarding clinical C. auris isolates and the use of antifungal susceptibility testing assay from 17 March 2015 to 1 February 2024. Meta-analysis was conducted using random-effects models to determine the estimated pooled prevalence of MDR-C. auris isolates and their antifungal resistance profiles from immunosuppressed humans. A total of 81 research studies were included in the final analysis, with the overall pooled prevalence of the three most important antifungal drugs; FLZ (92.5% | 95% CI: 89.5–94.7), VOR (49.0% | 95% CI: 37.6–60.4), and AmB (51.0% | 95% CI: 42.3–59.7). According to the subgroup analyses, FLZ-resistant C. auris was the most prevalent isolate observed in the five continents reporting compared to the VOR- and AmB-resistant C. auris having lower pooled prevalence. Further, higher pooled prevalence of MDR-C. auris isolates were observed from males (68.2%, n = 578) compared to females (37.1%, n = 283). Finally, the global pooled prevalence for mortality in immunosuppressed patients with MDR-C. auris from 13 research studies was 41.5% (95% CI: 29.9–54.2). This SR-MA study establishes the variation of MDR-C. auris resistance patterns observed from different continents and the importance to conduct further research studies using potent antifungal drugs. Accordingly, it is imperative to establish stringent surveillance on the increasing prevalence of antifungal resistance particularly in low-income regions with limited research resources to prevent increasing prevalence of MDR-C. auris.
Prostate Cancer Screening Practices Among High-Risk Patients: A Retrospective Analysis
Ghosh, Aditya , Sivasubramanian, Barath P., Asif, Rana H. , Barker, Steven A. , Dirisanala, Sudha, Ghosh, Aditya K , Barker, Steven, Robinson, Shane S. , Rynarzewska, Ania Izabela , Johnson, Andrew

Mayo Clinic

American Journal of Men's Health | November 20, 2025 | Volume: 19 | Issue: 6 | Pages: No page available

10.1177/15579883251392440 | PMID 41263152 Get It

Prostate cancer is the second most common cancer in U.S. men, with higher incidence and mortality among African Americans and those with genetic or familial risk. Despite guidelines promoting early detection, prostate-specific antigen (PSA) screening in primary care remains inconsistent. We assessed PSA screening patterns and the association between risk factors and testing. A retrospective analysis was conducted on men aged ≥40 seen at primary care clinics from 2020 to 2022. Risk scores were created based on the number of prostate cancer risk factors. Univariate and multivariate analyses assessed associations between the risk scores, PSA screening, and cancer diagnosis. Of 176,326 patients, 31.4% underwent PSA testing, rising to 78.1% with a risk score of 4. The predictive model was significant (χ 2 = 19,527.021, df = 11, p < .001). PSA testing odds were higher with Medicaid or commercial insurance (vs. Medicare) and lower for self-pay patients. Former and never smokers were more likely to be tested than current smokers. Age, African American race, and family history increased the odds of receiving PSA testing. Prostate cancer diagnosis reached 25% at a risk score of 5, with significant predictors including older age, African American race, family history, and mention of “prostate” in clinical notes. PSA screening remains underused in primary care, even among high-risk patients. More risk factors were linked to higher testing rates, but African American and low-income groups were under-tested. Provider education and decision-support tools may improve guideline adherence and equity.
An automated daily QA strategy for dosimetry and imaging guidance check of a novel PET/CT ring gantry linac
Ghimire, Sagar, Park, Yang Kyun, Gibbard, Grant, Tan, Jun , Banks, T. , Shen, Chenyang , Zhuang, Tingliang , Godley, Andrew , Banks, Thomas I , Prasad, Rameshwar , Jiang, Steve B , Cai, Bin, Tan, Jun

Mayo Clinic

Journal of Applied Clinical Medical Physics | November 19, 2025 | Volume: 26 | Issue: 12 | Pages: No page available

10.1002/acm2.70309 | PMID 41253712 Get It

Abstract Background The RefleXion X1 is a novel PET/CT‐guided ring gantry linac that introduces unique geometry and workflow compared to conventional systems. Existing QA guidelines (AAPM TG‐142, 148, 306) cover standard linacs and tomotherapy but do not address this platform's needs. Therefore, an automated daily QA solution is required to ensure accurate output, imaging guidance, and couch positioning, which motivated the development and evaluation of the workflow presented in this study. Purpose To develop and evaluate an automated, efficient, and comprehensive daily quality assurance (QA) workflow for a novel PET/CT‐guided ring gantry linear accelerator (RefleXion X1), incorporating tests for dosimetry, imaging guidance, and couch positioning accuracy. Methods An IMRT QA plan was designed following the CT scan of the TomoDose 2D diode detector array (Sun Nuclear, Melbourne, FL) within the RefleXion treatment planning system (TPS). Several spherical targets of varying sizes were contoured to conform the dose distribution to these targets and evaluate beam output, laser localization, profile constancy, and CT‐MV isocenter coincidence. Linear models correlating spatial location of dose peak with intentional shifts in different directions were developed and integrated into an in‐house analysis software, iQA, written in C#. The software was validated for robustness and successfully implemented in clinical practice. Results Validation with 42 intentional shifts showed submillimeter accuracy, with mean deviations of 0.2 mm (X), 0.1 mm (Y), and 0.79 mm (Z), and R 2 values ≥ 0.98. Over 1 year, daily QA data showed stable output constancy (1.006 ± 0.016), left/right target dose constancy (1.007 ± 0.005 and 0.996 ± 0.004), and consistent CT‐MV isocenter offsets (–0.335 ± 0.23 mm in X, 0.19 ± 0.19 mm in Y, and –0.544 ± 0.36 mm in Z). The software also detected a gradual output drift in between, prompting a timely linac adjustment. Conclusion This fully automated, single‐delivery QA workflow enables efficient and robust evaluation of multiple IGRT performance parameters. It improves standardization, reduces human error, and reliably monitors long‐term machine stability. The tools and methodology may be adopted by other clinics seeking a practical and automated daily QA solution. Future developments will focus on incorporating PET QA and rotational couch validations to further enhance the system's comprehensiveness and adaptability.
Comparative assessment of left common iliac vein compression in patients with hypermobile Ehlers-Danlos syndrome, hypermobility spectrum disorder and healthy controls – A retrospective single-centre study
Ogunlade, Samuel Busayo , Brown, Dillon M. , Rozen, Todd D. , Lewis, Andrew R. , Toskich, Beau , Fairweather, DeLisa , Knight, Dacre , Devcic, Zlatko , Ogunlade, Samuel B , Brown, Dillon, Rozen, Todd, Toskich, Beau B. , Knight, Dacre R T , Fairweather, DeLisa , Brown, Dillon, Bruno, Katelyn A.

Mayo Clinic

Phlebology: The Journal of Venous Disease | November 18, 2025 | Volume: 41 | Issue: 6 | Pages: 506-514

10.1177/02683555251400392 | PMID 41250613 Get It

Objectives Heritable connective tissue disorders (HCTDs), including hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobile spectrum disorder (HSD), have complex clinical manifestations, but the prevalence of left common iliac vein (LCIV) compression in these groups is not well known. This study aimed to compare the prevalence of significant LCIV compression in patients with hEDS, HSD, and healthy controls. Methods This retrospective, IRB-approved, single-center study analyzed 109 patients (25 hEDS, 64 HSD, 20 controls) who underwent contrast-enhanced abdominal and pelvic CT imaging from 2020 to 2023. LCIV compression was measured on axial CT, with >50% luminal narrowing defined as significant. Statistical analyses included chi-square tests, odds ratios, and t -tests. Interrater reliability was evaluated using intraclass correlation coefficients. Results Significant LCIV compression occurred in 68.0% of hEDS, 65.6% of HSD, and 35.0% of controls ( p = 0.034). Both hEDS ( p = 0.027) and HSD ( p = 0.015) groups had significantly higher compression rates than controls, with no statistically significant difference between the two clinical groups ( p = 0.831). Odds of compression were nearly fourfold greater in hEDS (OR 3.95) and HSD (OR 3.54) compared to controls. Conclusion LCIV compression is significantly more prevalent in patients with hEDS and HSD than in healthy controls, warranting further investigation of its clinical significance.
Spinal versus general anesthesia in robotic minimally invasive transforaminal lumbar interbody fusion: a comparative study on surgical outcomes
Llano, Juan P Navarro-Garcia de , Iyer, Harshvardhan , Sánchez-Garavito, Jesús E. , Safa, Adrian , Campo, Isabel Martin del , Graepel, Stephen , Patterson, Jennifer S., White, Kate E., Bojaxhi, Elird , Navarro-Ramírez, Rodrigo , Buchanan, Ian A. , Chen, Selby G. , Roberts, Andrew P, Martin Del Campo, Isabel, Iyer, Harshvardhan G , Ríos-Zermeño, Jorge , Roberts, Andrew P., ReFaey, Karim , Akinduro, Oluwaseun O. , Chen, Selby , Abode-Iyamah, Kingsley

Mayo Clinic

Journal of Neurosurgery: Spine | November 17, 2025 | Volume: 44 | Issue: 1 | Pages: 99-107

10.3171/2025.6.spine25442 | PMID 41105976 Get It

OBJECTIVE The implementation of robotics and spinal anesthesia (SA) in spine surgery is rapidly expanding, offering significant benefits for an increasingly complex and aging patient population with degenerative spinal disease. Here, the authors present the largest cohort to date evaluating the combined use of these two techniques in minimally invasive (MIS) transforaminal lumbar interbody fusion (TLIF). METHODS The authors retrospectively analyzed surgical outcomes of a series of patients who underwent robot-assisted (RA)–MIS TLIF under SA and general anesthesia (GA) at their institution from 2018 to 2024. Primary outcomes included operative times and postoperative pain intensity. Secondary outcomes included estimated blood loss, intraoperative complications, postoperative functional status, length of stay (LOS), and discharge status. To address potential confounders, a 1:1 propensity score–matching and regression analysis was implemented. Statistical analyses were conducted using Python. RESULTS A total of 209 patients underwent RA-MIS TLIF, with 31 (14.83%) receiving SA and 178 (85.17%) GA. After propensity score matching, the SA cohort demonstrated significantly shorter median total operating room (OR) time, total procedure time, time from entering the OR to skin incision, and time from closure to leaving the OR (all p < 0.01). Additionally, postoperative pain scores were significantly lower (p < 0.01), and LOS was significantly shorter (p < 0.01) in the SA cohort. Regression analysis, adjusting for potential confounders, further supported these findings. CONCLUSIONS RA-MIS TLIF fusion under SA is a safe and effective approach that significantly reduces operative time, postoperative pain, and hospital LOS in patients undergoing surgery for degenerative lumbar spine disease.
External Validation of the Fraser Equation for Estimation of Free Valproate Concentrations in Critically Ill Adults
Brown, Caitlin S. , Liu, JiTong , Riker, Richard R. , Lopez, Natasha , Rosenthal, Eric S. , Zafar, Sahar F. , Gagnon, David J. , Brown, Caitlin S , Liu, JiTong , Lopez, Natasha D , Webb, Andrew

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | November 17, 2025 | Volume: 45 | Issue: 12 | Pages: 831-839

10.1002/phar.70079 | PMID 41246825 Get It

ABSTRACT Background Critically ill patients may be overexposed to valproate because altered protein binding leads to a disproportionate free valproate fraction. The Fraser equation was derived and internally validated to estimate critically ill patients' free valproate concentrations, but it requires external validation. Methods Adult intensive care unit (ICU) patients at two academic centers with concurrently measured free and total valproate concentrations were included. Free valproate concentrations were estimated using the Fraser equation which includes total valproate, albumin and BUN concentration, and whether the patient received propofol or aspirin. The primary outcome was Fraser equation performance, assessed using Bland–Altman methods. Comparative performance against estimates from the Doré equation (an alternative predictive equation), therapeutic concordance using a target free valproate range of 5–15 mg/L, and equation improvements were explored. Results Overall, 315 patients and 556 free‐total valproate concentration pairs were included. The mean (±SD) age was 58 (±17) years and 90 (29%) patients were on valproate prior to hospital admission. The Fraser equation estimated free valproate concentrations were correlated with measured concentrations ( r = 0.728) with a negative bias (mean bias −2.77 mg/L, 95% LOA –18.9, 13.4). The Fraser equation increasingly underestimated measured concentrations as measured concentrations increased. 71% of Fraser equation estimates were therapeutically concordant (e.g., estimate and measured both within reference range) compared to 61.9% of Doré estimates ( p = 0.001). Fraser equation modifications led to minor performance improvements but did not overcome worsening underestimation with higher measured free valproate concentrations. Conclusion The Fraser equation was moderately accurate and corresponded with an appropriate interpretation for 71% of free valproate concentrations. Worse underestimation with higher measured free valproate concentrations suggests direct measurement of free valproate concentrations is warranted. While the Fraser equation could complement therapeutic decision making at centers where direct free valproate measurements are unavailable or slow to return, its accuracy is currently insufficient to replace direct measurement.
A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma
Landry, Alexander , Wang, Justin Z. , Patil, Vikas, Ajisebutu, Andrew, Gui, Chloe , Yefet, Leeor, Mamatjan, Yasin , Wei, Qingxia , Singh, Olivia, Mansouri, Sheila , Ehret, Felix , Capper, David , Cohen-Gadol, Aaron A, Behling, Felix , Sloan, Andrew E. , Chambless, Lola B. , Makarenko, Serge , Yip, Stephen , Tsang, Derek S. , Gao, Andrew , Aldape, Kenneth , Nassiri, Farshad , Zadeh, Gelareh , Santarius, Thomas , Selman, Warren R., Couce, Marta , Wen, Patrick Y. , Walbert, Tobias , Felicella, Michelle M. , Brodie, Chaya , Snyder, James P., Saladino, Andrea , Schichor, Christian , Tonn, Jörg‐Christian, Goldbrunner, Roland , Timmer, Marco , Schimdt, Nils Ole, Jenkinson, Michael D. , Millward, Christopher P. , Islim, Abdurrahman I. , Fl, Behling, Santacroce, Antonio , Schittenhelm, Jens , Raleigh, David R. , Butowski, Nicholas , Westphal, Manfred , Lamszus, Katrin , Mawrin, Christian , Kurz, Sylvia C. , Zada, Gabriel , Yip, Stephen, Zherebitskiy, Viktor, Hnenny, Luke, Dunn, Ian F. , Moliterno, Jennifer , McDermott, Michael , Vogelbaum, Michael A. , Aldape, Kenneth, Alkividias, Tzannis, Short, Susan , Bos, Eelke M. , Dincer, Alper , Paßlack, Peter, Ehret, Felix, Lopez, Clara, Arvaniti, Christina , Benjamin, Carolina , Jackson, Christina , Jeyaretna, Sanjeeva, Scartoni, Daniele , Amelio, Dante , Ivanidze, Jana , Kien, Duong Trung, Millareschavez, Miguel, AlThgafi, Malak, LeRhun, Emilie, Smee, Robert, Muirhead, William , Molina, Eric Suero, Julius, Vitowanu, Chen, J., Mrugała, Maciej M. , Castro, Ana Valeria , Mamatjan, Yasin , Capper, David , Tatagiba, Marcos , Barnholtz-Sloan, Jill S , Yip, Stephen , Aldape, Kenneth , Zadeh, Gelareh , Short, Susan C , Yefet, Leeor S. , Ellenbogen, Yosef , Liu, Jeff , Singh, Olivia , Tabatabai, Ghazaleh , Tatagiba, Marcos , Barnholtz‐Sloan, Jill S. , Mansouri, Alireza , Brastianos, Priscilla K. , Shih, Helen A. , Bi, Wenya Linda , Huang, Raymond Y. , Wen, Patrick Yung , Lee, Ian , Malta, Tathiane Maistro , Castro, Ana Valéria , Noushmehr, Houtan , DiMeco, Francesco , Pollo, Bianca , Kaufmann, Timothy J. , Lachance, Daniel Honore , Giannini, Caterina , Galanis, Evanthia , Raghunathan, Aditya , Hanemann, C. Oliver , Au, Karolyn , Galldiks, Norbert , Herold‐Mende, Christel C. , Sahm, Felix , Jungk, Christine , Jungwirth, Gerhard , Deimling, Andreas von , Drummond, Katharine Jann , Morokoff, Andrew P. , Renovanz, Mirjam , Fougère, Christian la , Perry, Arie , Ricklefs, Franz , Horbinski, Craig , Ng, Ho‐Keung , Snuderl, Matija , Sulman, Erik P. , Cohen‐Gadol, Aaron , Javadpour, Mohsen , Fountain, Daniel Mark , Mathiesen, Tiit Illimar , Pathmanaban, Omar Nathan , Boutros, Paul C. , Fountas, Konstantinos N. , Walsh, Kyle M. , Carvalho, Bruno , Maas, Sybren L. N. , Deng, Maximilian Y. , Mehta, Minesh P. , Odia, Yazmín , Everson, Richard G. , Balogun, James , Calabrese, Evan , Karschnia, Philipp , Teske, Nico , Fariselli, Laura , Greve, Tobias , Ivan, Michael E , Palmer, Joshua D. , Ostrom, Quinn T. , Youngblood, Mark W. , Emerson, Sam, Weller, Michael , Martínez-Pérez, Rafael , Mukherjee, Raj, Cervio, Andrés , Turner, Clinton P. , Chen, Jiawei, Karmur, Brij S. , Neth, Bryan J.

Mayo Clinic

Neuro-Oncology | November 15, 2025 | Volume: 28 | Issue: 2 | Pages: 430-439

10.1093/neuonc/noaf237 | PMID 41259653 Get It

Abstract Background DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patients. To allow for seamless integration of these complementary models into clinical practice, a practical framework is needed. Methods We leveraged a cohort of nearly 2000 surgically-treated meningiomas with DNA methylation profiling and clinical outcomes data. Existing methylation-based prediction models were dichotomized to yield four risk groups: low and high recurrent risk, each with RT sensitive and resistant subgroups. Risk groups were correlated with progression-free survival in the context of existing biomarkers including extent of resection and WHO grade. Results We first demonstrated that all risk groups benefit from gross total resection. All “high-risk, RT sensitive” tumors (n = 306, 15.7%) also benefited from adjuvant RT: after GTR, median PFS increased from 4.68 (4.13-9.48) years to not reached (P = .003); after subtotal resection (STR), from 2.12 (1.59-3.02) to 4.09 (3.41-not reached) years (P = .004). “Low-risk, RT sensitive cases” (n = 1207, 61.8%) also benefited from RT after STR (median PFS 7.39 (6.66-12.8) vs. 16.53 (10.35-not reached) years, P = .03), suggesting that RT be considered in these patients. Neither “low-risk RT resistant” (n = 84, 4.3%) nor “high-risk RT resistant” (n = 356, 18.2%) cases benefited from RT, and the latter group was associated with universally poor outcomes. Conclusions We identify methylation-defined risk groups of meningioma for which additional benefit is gained from adjuvant RT, leading to a clinical decision-making framework for straightforward integration of molecular models into clinical practice.